LONDON, December 7, 2011 /PRNewswire/ --
Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading RNA interference (RNAi) therapeutics company, announces a positive outcome from the oral hearing on 6 December 2011 at the European Patent Office (EPO) over opposition to Silence's granted European Patent EP 1 536 827 "Further use of protein kinase N beta".
The granted patent refers to the gene target PKN3, protein kinase N beta, targeted by Silence's lead program Atu027, which is currently in a Phase I clinical study. The Opposition division of the EPO decided to uphold the patent in amended form.
Claim one of the patent relates to the use of protein kinase N beta as a downstream target of the PI3 kinase pathway. Claim two relates to the use of protein kinase N beta as a downstream drug target of the PI3 kinase pathway in a screening process. Both of these claims are maintained as granted, and also the use claims where manufacture of a diagnostic agent is based on use of protein kinase N beta as such (or use of antibodies, spiegelmers, aptamers, ribozymes, antisense molecules and siRNA molecules directed against protein kinase N beta and the nucleic acid molecule coding for these, respectively).
In connection with the use claims where protein kinase N beta as such (or antibodies, spiegelmers, aptamers, ribozymes, antisense molecules and siRNA molecules directed against protein kinase N beta and the nucleic acid molecule coding therefore, respectively) are used for the manufacture of a medicament, the diseases for which such medicament is to be used are now restricted to metastatic cancers. This is the focus of Silence's currently ongoing Atu027 Phase I study with late-stage cancer patients.
Commenting on today's announcement, Thomas Christély, Chief Exe
|SOURCE Silence Therapeutics Plc|
Copyright©2010 PR Newswire.
All rights reserved